HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.106.038091v1 48/8/1245    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dimitrakopoulou-Strauss, A. Articles by Strauss, L. G. Search for Related Content PubMed PubMed Citation Articles by Dimitrakopoulou-Strauss, A. Articles by Strauss, L. G.

⁶⁸Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with ¹⁸F-FDG

¹ Medical PET Group–Biological Imaging, Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany; ² Division of Surgical Oncology and Thoracic Surgery, Surgical Clinic, Klinikum Mannheim, University of Heidelberg, Heidelberg, Germany; ³ Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany; ⁴ Division of Radiological Chemistry, Department of Radiology, University Hospital Basel, Basel, Switzerland; and ⁵ Department of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany

Correspondence: For correspondence or reprints contact: Antonia Dimitrakopoulou-Strauss, MD, Medical PET Group–Biological Imaging (E0601), Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany. E-mail: ads{at}ads-lgs.de or a.dimitrakopoulou-strauss{at}dkfz.de

Dynamic PET studies with a ⁶⁸Ga-bombesin analog, DOTA-PEG₂-[D-Tyr⁶, ß-Ala¹¹,Thi¹³,Nle¹⁴] BN(6-14) amide (⁶⁸Ga-BZH₃; DOTA is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, and PEG is ethylene glycol [2-aminoethyl-carboxymethyl ether]), were performed on patients with gastrointestinal stromal tumors (GIST) to investigate the impact of complementary receptor scintigraphy on diagnosis and the potential of a radionuclide treatment. Furthermore, dynamic ¹⁸F-FDG studies were performed on the same patients. Methods: This study comprised 17 patients with GIST. All patients were scheduled for therapy with imatinib because of unresectable primary or recurrent GIST or because of metastatic disease. Dynamic PET scans using ⁶⁸Ga-BZH₃ and ¹⁸F-FDG were obtained on 2 consecutive days. Multivariate analysis was used to evaluate the kinetic data. Standardized uptake values (SUVs) were calculated, and a compartmental model (2-tissue) and noncompartmental model were used for data evaluation of both tracers. Results: Fourteen of 17 patients (25/30 lesions) were positive for uptake on ¹⁸F-FDG imaging, whereas ⁶⁸Ga-BZH₃ demonstrated an enhanced accumulation in 7 of 17 patients (8/30 lesions). Thirteen lesions were confirmed by histologic examination, and the remaining 17 were confirmed by follow-up. One recurrent tumor in the stomach could not be delineated on ¹⁸F-FDG imaging but showed enhanced ⁶⁸Ga-BZH₃ uptake. The median SUV for ⁶⁸Ga-BZH₃ was 3.3, in comparison with 7.9 for ¹⁸F-FDG. Best-subset analysis demonstrated that the global SUV (55–60 min after injection) for ¹⁸F-FDG was primarily dependent on k3, followed by k1. Multivariate analysis did not show a significant correlation between the kinetic parameters (k1–k4, fractional blood volume, and SUV) for ¹⁸F-FDG and bombesin. Conclusion: ⁶⁸Ga-BZH₃ may be helpful for diagnostic reasons in a subgroup of patients with GIST, as in the case of negative ¹⁸F-FDG findings and suspicion of viable tumor tissue. The meaning of the enhanced ⁶⁸Ga-BZH₃ uptake is open at the moment.

Key Words: ⁶⁸Ga-bombesin • ¹⁸F-FDG • GIST • PET • kinetic modeling

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  

This article has been cited by other articles:

				J. C. Reubi and H. R. Maecke Peptide-Based Probes for Cancer Imaging J. Nucl. Med., November 1, 2008; 49(11): 1735 - 1738. [Abstract] [Full Text] [PDF]

				C. Mussi, H.-U. Schildhaus, A. Gronchi, E. Wardelmann, and P. Hohenberger Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1 Clin. Cancer Res., July 15, 2008; 14(14): 4550 - 4555. [Abstract] [Full Text] [PDF]

				R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]